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Abstract
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Importance—Evidence is mounting that achromatopsia is a progressive retinal degeneration, and
treatments for this condition are on the horizon.
Objectives—To categorize achromatopsia into clinically identifiable stages using spectraldomain optical coherence tomography and to describe fundus autofluorescence imaging in this
condition.
Design, Setting, and Participants—A prospective observational study was performed
between 2010 and 2012 at the Edward S. Harkness Eye Institute, New York-Presbyterian
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Hospital. Participants included 17 patients (aged 10-62 years) with full-field electroretinographyconfirmed achromatopsia.
Main outcomes and Measures—Spectral-domain optical coherence tomography features and
staging system, fundus autofluorescence and near-infrared reflectance features and their
correlation to optical coherence tomography, and genetic mutations served as the outcomes and
measures.

Author Manuscript

Results—Achromatopsia was categorized into 5 stages on spectral-domain optical coherence
tomography: stage 1 (2 patients [12%]), intact outer retina; stage 2 (2 patients [12%]), inner
segment ellipsoid line disruption; stage 3 (5 patients [29%]), presence of an optically empty space;
stage 4 (5 patients [29%]), optically empty space with partial retinal pigment epithelium
disruption; and stage 5 (3 patients [18%]), complete retinal pigment epithelium disruption and/or
loss of the outer nuclear layer. Stage 1 patients showed isolated hyperreflectivity of the external
limiting membrane in the fovea, and the external limiting membrane was hyperreflective above
each optically empty space. On near infrared reflectance imaging, the fovea was normal,
hyporeflective, or showed both hyporeflective and hyperreflective features. All patients
demonstrated autofluorescence abnormalities in the fovea and/or parafovea: 9 participants (53%)
had reduced or absent autofluorescence surrounded by increased autofluorescence, 4 individuals
(24%) showed only reduced or absent autofluorescence, 3 patients (18%) displayed only increased
autofluorescence, and 1 individual (6%) exhibited decreased macular pigment contrast. Inner
segment ellipsoid line loss generally correlated with the area of reduced autofluorescence, but
hyperautofluorescence extended into this region in 2 patients (12%). Bilateral coloboma-like
atrophic macular lesions were observed in 1 patient (6%). Five novel mutations were identified (4
in the CNGA3 gene and 1 in the CNGB3 gene).

Author Manuscript

Conclusions and Relevance—Achromatopsia often demonstrates hyperautofluorescence
suggestive of progressive retinal degeneration. The proposed staging system facilitates
classification of the disease into different phases of progression and may have therapeutic
implications.

Author Manuscript

Achromatopsia is a congenital cone photoreceptor disorder with autosomal recessive
inheritance and an estimated prevalence of 1 in 30 000. Affected individuals usually have
congenital nystagmus, poor visual acuity, photophobia, and lack of color discrimination.1
Funduscopic examination is often normal, although pigmentary mottling and atrophic
changes may be observed in the macula.2 Electroretinography (ERG) reveals absent or
profoundly reduced cone responses with normal or mildly subnormal rod function.3 These
features establish the clinical diagnosis of achromatopsia. Causative mutations have been
identified in the CNGB3 (Chr. 8q21.3), CNGA3 (Chr. 2q11.2), GNAT2 (Chr.1p13.3),
PDE6C (Chr. 10q23.33), and PDE6H (Chr. 12p12.3) genes, with CNGB3 being the most
commonly affected.4-9 All of these genes encode functionally important components of the
cone photo-transduction cascade.
Achromatopsia has traditionally been thought of as a stationary disease and was classified as
part of the cone dysfunction syndromes rather than the cone dystrophies.1 However, findings
in animal models and in human studies have suggested that achromatopsia is rather a
progressive degeneration. Mouse models of achromatopsia have demonstrated a progressive
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loss of the cone cells with age,10,11 canine models have shown detectable cone ERG
function in young pups that becomes nonrecordable in mature dogs,12 and human studies3 of
achromatopsia have revealed deterioration in cone ERG function over time. Recently,
studies2,13 have used spectral-domain optical coherence tomography(SD-OCT) to show agedependent correlations with reduced outer nuclear layer (ONL) and total retinal thicknesses,
disruption of the inner segment ellipsoid (ISe) line, the presence of an optically empty space
(OES) (also called a bubble or hyporeflective zone) in the cone photoreceptor layers, and
retinal pigment epithelium (RPE) disruption. Most recently, a longitudinal study14
evidenced progressive structural degeneration in children younger than 10 years with
achromatopsia. Over a mean follow-up period of 16 months, these individuals showed a
decrease in central macular and ONL thicknesses as well as new or enlarging disruption of
the ISe line.

Author Manuscript
Author Manuscript

Treatments for achromatopsia are on the horizon. Cone-targeted gene therapy has shown
success in mouse and canine studies,15-17 in which it improved cone survival, recovered
cone ERG amplitudes to near-normal levels, and corrected visual acuity. Another promising
treatment is the use of neuroprotective compounds, most notably ciliary neurotrophic factor
(CNTF), which has been shown18 to inhibit progressive degeneration of rod and cone
photoreceptors in a variety of animal models and clinical trials. It also induced cone outersegment regeneration in a rat model of retinal degeneration19 and improved cone ERG
function and vision in dogs with achromatopsia.18 Therefore, long-term treatment with
CNTF starting at early stages of degeneration could be a viable strategy for preservation and
rescue of cone photoreceptors. However, success with either gene- or CNTF-based therapy
would require that cone photoreceptors are present and viable within the macula. Although
there are still many hurdles to overcome, stem cell–based therapy is being pursued as a
potential treatment of retinal degenerative diseases and may become an option for patients
who have already lost their foveal cones. However, if RPE atrophy is also present,
replacement of the RPE would be an additional consideration and may result in more
challenging treatment.20,21 Therefore, a system of clinically distinguishable stages may
facilitate better classification of the disease at different phases of its progression and guide
therapeutic decisions, not only in clinical trials but in clinical settings as well. In the present
study, we propose such a system, which is based on SD-OCT because it provides highresolution imaging of retinal architecture and is widely available and easy to perform.

Author Manuscript

Another imaging modality, which is widely used in the diagnosis, characterization, and
follow-up of many retinal disorders, is fundus autofluorescence (AF). This technique
enables visualization of the distribution of lipofuscin across the posterior pole. Lipofuscin
contains a complex mixture of fluorescent molecules that are by-products of the visual cycle
and are accumulated in the RPE through phagocytosis of photo-receptor outer segments.22
Although the diffuse increase of lipofuscin with aging is physiologic,23 abnormal
distributions are common in many retinal diseases and result in topographic changes in
intensity on AF images.24-27 Decreased AF is typically considered to be a marker of RPE
atrophy, but it may also indicate photoreceptor loss (arrested bisretinoid deposition)
combined with photodegradation of RPE lipofuscin.28 On the other hand, elevated AF
suggests an increased metabolic load at an intermediate stage before cell loss and
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atrophy.22,26 For example, adenosine triphosphate binding cassette A4 (ABCA4)–related
disease and cone-rod dystrophies of other origins can present with hyperautofluorescent
rings that surround decreased or absent foveal AF and progressively expand with time.26,29
These rings colocalize with reduced visual sensitivity27 and, across the annulus, the ISe line
may not be visible on SD-OCT.30 Given the mounting evidence for the progressive nature of
achromatopsia, one may expect to observe AF features similar to those seen in other
progressive degenerations. We describe these features and compare them with structural
changes as observed on SD-OCT.

Methods

Author Manuscript

Seventeen patients (11 [65%] males, 6 [35%] females; mean [SD] age, 31 [16] years; range,
10-62 years) with achromatopsia were included in this study. There were 4 sibling pairs. The
study was performed between February 2010 and May 2012 at the Edward S. Harkness Eye
Institute. The research adhered to the tenets of the Declaration of Helsinki, institutional
review board approval was granted, written informed consent was obtained from
participants or parents/guardians, and Health Insurance Portability and Accountability Act
compliance was maintained. Participants received no monetary compensation. Experienced
electrophysiologists performed full-field ERGs according to the International Society for
Clinical Electrophysiology of Vision standards.31 The diagnosis was based on clinical
presentation of poor visual acuity since birth, congenital nystagmus, photophobia, severe
color vision defects, and absent or residual cone responses with normal rod responses on
ERG. Participants were screened in a step-by-step strategy for mutations in the CNGB3
(OMIM 605080), CNGA3 (OMIM 600053), GNAT2 (OMIM 139340), PDE6C (OMIM
600827), and PDE6H (OMIM 601190) genes, as previously described.5,6

Author Manuscript
Author Manuscript

All patients underwent a detailed ophthalmic examination; imaging included color fundus
photography as well as near-infrared reflectance (NIR), AF, and SD-OCT imaging
performed with a confocal scanning laser ophthalmoscope (Spectralis HRA+OCT,
Heidelberg Engineering). Autofluorescence images (488 nm excitation, 500-680 nm barrier
filter) were composed of at least 9 single frames (30° × 30° field, highspeed setting), which
were computationally averaged to improve signal to noise ratio. However, fewer frames
were used in some cases when image acquisition was difficult. Spectralis OCTs were
performed as single horizontal line scans across the foveal center. The high-resolution
setting was used, and 40to 100 frames per scan were obtained; however, these were adjusted
when severe nystagmus and poor fixation impaired OCT tracking. Each SD-OCT scan was
correlated in real time with either an NIR (NIR-OCT) or AF (AF-OCT) image (Eye
Explorer software; Heidelberg Engineering). The NIR-OCT images were obtained for all
participants; however, AF-OCT imaging was possible only with 6 individuals (35%)
because of difficult image acquisition. For the remaining 11 cases (65%), aligning AF to
NIR images with software written in MATLAB, version 7.10 (http://www.mathworks.com/
products/matlab/) enabled accurate correlation between AF and SD-OCT.
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Results
Clinical characteristics of the patients are summarized in Table 1. All participants had
photophobia and congenital nystagmus. Snellen best-corrected visual acuity ranged from
20/80 to 20/200 (mean, 20/150) and was generally symmetrical.

Author Manuscript

Participants demonstrated largely symmetrical findings on all imaging modalities. On color
fundus photography, 7 patients (41%) showed RPE alterations: 3 of these (18%) were
mottled RPE changes and 4 (23%) were a distinct area of RPE atrophy. Another patient had
bilateral coloboma-like atrophic macular lesions, with excavation down to the sclera (further
detail is available in the Supplement [eAppendix 1]). Of the patients with no visible RPE
changes, 2 had a darkened fovea (12%), 2 showed a hypopigmented foveola (12%), and in 5
cases, the fovea appeared normal (29%). On NIR imaging, 9 patients (53%) had a
hyporeflective fovea, with a distinct central zone of hyperreflectance in 3 of these cases
(18%). The fovea in 5 patients (29%) showed mixed hyporeflective and hyperreflective
features, and in 3 individuals (18%) appeared normal.

Author Manuscript

Autofluorescence imaging was more sensitive for detecting pathologic features than both
color fundus photography and NIR imaging and demonstrated abnormalities in all patients.
An area of reduced AF was observed in the central macula of 13 participants (76%). It was
often in the shape of a horizontal oval and was limited to the fovea, although 2 patients
(12%) had larger lesions extending into the parafovea. In 8 cases (47%), a region of
hyperautofluorescence surrounded the reduced AF, and 1case (6%) showed bordering
hyperautofluorescence limited to the inferior and temporal para-fovea. Of the 4 patients
(24%) without reduced AF, 3 individuals (18%) demonstrated hyperautofluorescence and 1
patient (6%) showed decreased macular pigment contrast. The area of
hyperautofluorescence was generally greater in horizontal than vertical extent and ranged in
width from a thin rim surrounding reduced AF to a wider region that extended into the parafovea.

Author Manuscript

On SD-OCT, 13 participants (76%) had foveal hypoplasia.32 The ISe line was disrupted in
15 patients (88%), and 8 of these (47%)showed varying degrees of RPE disruption.
Achromatopsia was categorized based on SD-OCT into 5 stages (Figure 1; retinal layer
nomenclature is listed in the Supplement [eFigure]). Stage 1 disease (2 patients [12%]) was
characterized by intact outer retinal structure, although subtle discontinuities were observed
in the ISe line. The cone outer segment tip layer appeared normal in 1 of these patients (6%)
and was present but thinned toward the foveal center in the other patient (6%). We also
observed isolated hyperreflectivity of the external limiting membrane (ELM) in the fovea
and flattening of the ISe line posterior to the foveola. Stage 2 disease (2 patients [12%]) was
defined as disruption of the ISe line but without the presence of an OES. The photoreceptor
inner segment layer was present in these patients, although it was hyperreflective in 1 patient
(6%) above and slightly beyond the site of ISe line disruption, where it likely represented a
transitional phase toward inner segment breakdown. We observed interruption of the cone
outer segment tip layer in 1 of these patients (6%), but image quality in the other individual
(6%) was insufficient to differentiate this feature. Stage 3 disease (5 patients [29%])
demonstrated an OES with loss of photoreceptor inner and outer segments, but there was no
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visible RPE damage. In most cases, we observed extension of the OES into the ONL. Stage
4 disease (5 patients [29%]) was defined as the presence of an OES with partial RPE
disruption. The ELM above each OES was hyperreflective, and it was thickened in 3 of
these cases. Stage 5 disease (3 patients [18%]) was defined as complete RPE disruption
and/or loss of the ONL. One of these cases (6%) had complete RPE disruption and loss of
the OES, 1 had both complete RPE disruption and ONL loss (6%), and the third patient
(6%) had bilateral coloboma-like macular lesions. There was no significant difference in age
between SD-OCT stages of disease (1-way analysis of variance F = 0.78; P = .56), although
both patients with stage 1 achromatopsia were younger than 24 years, and stage did not
correlate with visual acuity or with which gene was affected by mutation (CNGB3 vs
CNGA3), which is in line with the lack of geno-type-phenotype correlations previously
described.2,33 There was some degree of phenotypic concordance between sibling pairs,
with siblings in 2 of the 4 pairs displaying the same phenotype on all imaging modalities
(pairs 2 and 3; both stage 4). Although both of the oldest siblings (pair 4) had stage 5 disease
and displayed the largest lesions of the study group, only one demonstrated bilateral
coloboma-like macular lesions. In sibling pair 1, the brother had stage 3 disease, but the
sister, of similar age, had stage 1. More detail is available in the Supplement (eAppendix 2).

Author Manuscript

Various comparisons were made between imaging modalities (Figure 2). The region of ISe
loss generally corresponded to the area of reduced AF, although hyperautofluorescence
extended into this region in 2 patients (12%). Near-infrared reflectance imaging usually
displayed an area of hyporeflectance that correlated with the region of ISe line disruption.
Patients with an intact outer retinal structure did not have reduced foveal AF and appeared
normal on funduscopy and NIR imaging. Spectral-domain OCT evidenced RPE disruption
in all cases in which RPE changes were visible on funduscopy, and these patients showed
corresponding hyperreflective features on NIR imaging and greatly reduced or absent AF.
No other imaging modality in this study reliably differentiated between all SD-OCT stages.
Genetic analysis revealed causative homozygous or compound heterozygous mutations in
CNGA3 for 7 participants (41%) and in CNGB3 for 3 people (18%); single heterozygous
mutations in CNGB3 were identified in 2 participants (12%). Five mutations (29%) were
novel (4 [24%] in CNGA3 and 1 [6%] in CNGB3). No mutations were detected in GNAT2,
PDE6C, or PDE6H. The observed genotypes are documented in Table 2 (further detail is
available in the Supplement [eAppendix 3]).

Discussion
Author Manuscript

One objective of our study was to evaluate the AF features of achromatopsia. Being a
primary cone photoreceptor disorder, the area of hyperautofluorescence found in most (12
[71%]) of our patients likely reflects increased cone outer segment turnover, which is
marked by intensified bisretinoid deposition in the RPE. Low calcium levels in CNGA3- and
CNGB3-deficient cones may affect endoplasmic reticulum metabolism and outer segment
biogenesis. Given the evidence from previous studies2,3,13,14 that achromatopsia is a
progressive disorder, our finding of hyperautofluorescence is not surprising. However, the
observed hyperautofluorescence was often subtle and, in 3 patients (18%) with early-stage
disease, was visible only on one side of the fovea. For the cases without
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hyperautofluorescence, the slow rate of photoreceptor damage in combination with masking
of the AF signal by macular pigment may have resulted in the AF images not manifesting
the abnormalities in outer segment turnover. Green light AF, which excludes macular
pigment, and estimation of macular pigment density could be helpful for a more precise
degree of autofluorescence derived from RPE lipofuscin in the macula. This assessment may
be further aided by AF quantification.34

Author Manuscript

Patients with RPE disruption demonstrated on SD-OCT displayed a corresponding area of
greatly reduced or absent AF. However, 5 (29%) of the 7 individuals (41%) who had ISe
line disruption but no RPE damage also showed reduced AF (less marked than in those with
RPE atrophy), which was localized to regions of photoreceptor loss. This suggests that the
reduced AF in these patients arises from arrested deposition of bisretinoids in the RPE (due
to the absence of photoreceptors) coupled with lipofuscin depletion due to
photodegradation.28 The area of hyperautofluorescence was generally observed in regions
where the ISe line was present, indicating that it preceded photoreceptor loss. However, in 2
patients (12%; both with stage 3 achromatopsia) it extended into the region of ISe loss,
likely reflecting areas where photodegradation had not yet substantially reduced AF
intensity. Longitudinal data in future studies would be helpful to evidence changes in AF
intensity over time and correlate them with features observed on SD-OCT.

Author Manuscript

We believed SD-OCT to be the optimal modality with which to stage achromatopsia
because it provides high-resolution imaging of retinal architecture and is widely available
and easy to perform. In contrast, other techniques, such as adaptive optics and multifocal
ERG, are difficult to perform in achromatopsia because of the nystagmus and poor fixation
inherent to this condition. These techniques are therefore not practical for a clinically
accessible staging system, but may be useful adjunctive measures for tracking structural and
functional responses to treatment in clinical trials. Our system relies on SD-OCT alone for
simplicity but also because no other imaging modality in our study reliably differentiated
between all stages. It is primarily based on the integrity of cone photoreceptors, but also
takes into account damage to the RPE. The degree of structural degeneration categorized by
this staging system may guide selection of optimal treatment strategies not only for clinical
trials, but in clinical settings as well. Although our study was limited by its cross-sectional
design and fairly small sample size, our assessment of the clinical course of achromatopsia
was guided by the age-dependent correlations demonstrated in previous cross-sectional SDOCT studies2,13 and by the dynamic retinal changes evidenced in a recent longitudinal
study.14

Author Manuscript

Patients with stage 1 achromatopsia had an intact outer retinal structure, with only subtle
discontinuities in the ISe line and a relatively preserved cone outer segment tip layer in the
fovea. This indicates that the cone photoreceptors maintained structural integrity; these
patients would therefore be ideal candidates for gene therapy. They would also be most
likely to benefit from treatment with CNTF, which may arrest cone degeneration and
possibly also recover their function, as it did in dogs with CNGB3 mutations.18 An
interesting feature that we observed in these cases was increased reflectivity of the foveal
ELM. This was observed in the absence of hyperreflective foveal cone outer segments,
which was shown to be a transitional phase toward ISe line disruption,14 and thus the ELM
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appears to be the first structure to demonstrate hyper-reflectance. Although this feature was
subtle in one patient, it was more prominent and extended over a larger region in the other
patient, where it corresponded to the region of cone outer segment tip thinning. The
observed ELM hyperreflectivity may be explained by a greater difference in refractive index
as tissue below it breaks down, for which it appears to be a sensitive indicator. Therefore,
isolated hyperreflectivity of the ELM may represent an early sign of cone degeneration
detectable on SD-OCT.

Author Manuscript

Stage 2 was defined by disruption of the ISe line. Although these patients had loss of the
photoreceptor outer segments, the photoreceptor inner segment layer was relatively spared.
Gene therapy has not been shown to regenerate cone cells, but long-term treatment with
CNTF induced cone outer segment regeneration in a rat model of retinal degeneration.19
Therefore, there may be potential for CNTF to not only arrest the degenerative process but
also to regenerate the focal cone damage in these patients.
Photoreceptor damage was more extensive in patients with stage 3 and 4 disease, who
showed loss of both the photoreceptor inner and outer segments in the OES. It is suspected
that many cone nuclei are ectopically located in these patients (Supplement [eAppendix 4]).
However, the ONL was still present, which suggests that these patients retain some viable
and correctly located nuclei. They may therefore experience some success with treatments
aimed at photoreceptor regeneration, although photoreceptor replacement with stem cell
therapy may be the most suitable treatment. Of note are 2 reported13,14 cases of patients who
presented with an OES beneath an only intermittently disrupted ISe line (Supplement
[eAppendix 5]).

Author Manuscript

Patients with stage 4 achromatopsia demonstrated partial RPE disruption within the region
of the OES. Previous studies2,33 found RPE atrophy only in olderage groups, and we
observed several patients with an OES but with no signs of RPE disruption. This suggests
that RPE disruption is a late manifestation in achromatopsia. The secondary RPE damage
may be explained, at least in part, by the toxic effects of lipofuscin accumulation in these
cells.35-37 When considering an optimal treatment protocol for patients with RPE disruption,
regeneration or replacement of the RPE would be an additional consideration and may result
in more challenging treatment.20,21 Ciliary neurotrophic factor has been shown38 to increase
RPE survival in cultures of human fetal RPE cells and therefore may have the additional
benefit of preventing or stabilizing RPE damage in patients with achromatopsia.

Author Manuscript

In stage 5 disease, there was complete RPE disruption and/or loss of the ONL. Other
studies2,33 have illustrated similar cases of achromatopsia. Given that foveal photoreceptors
and/or RPE cells are not viable in these patients, they would require replacement with stem
cell therapy. However, the case with bilateral coloboma-like atrophic macular lesions would
require more extensive regenerative approaches.
Although animal models have shown promising results, knowledge regarding the extent of
regeneration with different treatment approaches is still in the early stages, and much work
needs to be done to determine how humans with achromatopsia will respond to the proposed
therapies. Although this staging system is based on which treatments may restore the outer
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retina, to successfully restore vision, the inner retinal cells and central visual pathways will
need to usefully process the new peripheral input from functional cones. Success in this
regard may be age dependent, with one study17 showing that older dogs were less likely than
younger dogs to show restoration of cone ERG responses after gene therapy, even though
many cones were present and structurally normal, and another study16 demonstrating that
gene therapy recovered ERG amplitudes in older mice but without a corresponding
improvement in visual acuity.

Author Manuscript

Limitations of the study include its relatively small sample size, which provided few patients
in each SD-OCT stage. A larger study may afford more consistent correlations of the stages
with the progressive features of multimodal imaging as well as with age and visual acuity.
This study was also limited by the lack of confirmed disease-causing mutations in 7 patients;
total genome sequencing may aid in elucidating genotype-phenotype relationships. Given
the cross-sectional design of this study, longitudinal data may provide a better understanding
of the pathophysiology of achromatopsia and may contribute further evidence of its
progressive nature.

Conclusions
Achromatopsia often exhibits AF features that suggest progressive retinal degeneration.
Autofluorescence imaging provides a modality to topographically visualize the pathologic
changes and reveals features that are not otherwise appreciated; it may therefore provide
some additional clinical usefulness, as suggested by the observations in this report. The
foveal ELM appears to be the first structure to develop hyper-reflectivity and may be an
early sign of cone degeneration in patients with intact outer retina. The proposed SD-OCT
staging system may be used to guide therapeutic decisions.

Author Manuscript
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Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Staging System and Corresponding Fundus Autofluorescence (AF) Images
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Spectral-domain optical coherence tomography (SD-OCT) stages (left) and corresponding
fundus AF images (right) in patients with achromatopsia. Stage 1: A, Outer retinal structure
is intact but there is flattening and subtle discontinuity of the inner segment ellipsoid (ISe)
line posterior to the foveola. The cone outer segment tip (COST) layer (left arrowhead) is
relatively spared, although it is thinned toward the foveal center, and the external limiting
membrane is hyperreflective (right arrowhead) in this region. B, The corresponding AF
image shows decreased macular pigment contrast and fine punctate hyperautofluorescent
dots scattered across the macula (the dots were also visible on color fundus photography
[yellow] and near-infrared reflectance imaging [hyperreflective]). Stage 2: C, The ISe line is
disrupted. Note interruption of the COST layer and hyperreflectivity of the photoreceptor
inner segments. D, The AF image shows centrally reduced AF with subtle
hyperautofluorescence around the inferotemporal fovea (arrowhead). Stage 3: E, This case
demonstrates the classic optically empty space (OES), with absent photoreceptors in the
fovea, but the retinal pigment epithelium (RPE) appears intact. F, The AF image shows
hyperautofluorescence resulting in a stippled foveal appearance. Stage 4: G, An OES and
partial RPE disruption (choroidal hyperreflectance is indicated with arrowheads). Note the
reflective material, possibly photoreceptor debris, at the roof of the OES (also seen in E). H,
The AF image displays a central area of greatly reduced AF but no observable
JAMA Ophthalmol. Author manuscript; available in PMC 2015 May 07.

Greenberg et al.

Page 13

Author Manuscript

hyperautofluorescence. Stage 5: I, Complete RPE disruption and loss of the outer nuclear
layer. J, The AF image demonstrates a larger lesion with a surrounding hyperautofluorescent
ring and a central region of absent AF.
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Figure 2. Multimodal Imaging
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Images in patients with stage 3 (case 5), stage 4 (case 12), and stage 5 (case 15)
achromatopsia are shown. Imaging modalities (top to bottom) are spectral-domain optical
coherence tomography (SD-OCT), color fundus photography (color), near-infrared
reflectance (NIR), and fundus autofluorescence (AF). Correlations between imaging
modalities are indicated with vertical (white) and horizontal (green) lines. In stage 3, the
fovea is darkened (color) and shows decreased reflectance (NIR) and reduced AF
surrounded by hyperautofluorescence (AF imaging). Spectral-domain OCT demonstrates a
characteristic optically empty space (OES), but the retinal pigment epithelium (RPE)
appears intact. Note the reflective material within the OES and the thickened external
limiting membrane. The extent of inner segment ellipsoid (ISe) line loss correlates with the
hyporeflective area on NIR. The AF image reveals extension of the hyperautofluorescence
into the region of ISe loss, although it is less intense than in the surrounding area. In stage 4,
the fovea reveals mottled RPE changes (color), mottled hyporeflectivity and
hyperreflectivity (NIR), and greatly reduced AF surrounded by a thin hyperautofluorescent
rim (AF imaging). Spectral-domain OCT shows an OES and partial RPE disruption. The
region of ISe loss corresponds to the lesions seen on color, NIR, and AF. In stage 5, the
fovea is dark with a well-defined central area of RPE atrophy (color), is hyporeflective with
a distinct highly reflective central area (NIR), and is hypoautofluorescent with a central
region of greatly reduced AF and a surrounding hyperautofluorescent ring (AF imaging).
Spectral-domain OCT evidences complete RPE disruption and loss of the OES. The region
of ISe loss (solid vertical lines) correlates with the dark, hyporeflective, and
hypoautofluorescent areas on color, NIR, and AF, respectively. The RPE disruption
(interrupted vertical lines) corresponds to the atrophic, hyperreflective, and greatly
hypoautofluorescent central areas on color, NIR, and AF, respectively. Note that the RPE is
relatively spared outside of the disrupted zone.
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Patient/Sex/ Age, y

Excavation of macula down to
sclera

Atrophic macular lesion

Well-defined area of RPE atrophy

Well-defined area of RPE atrophy

Well-defined area of RPE atrophy

Mottled RPE changes

Mottled RPE changes

Mottled RPE changes

Normal

Hypopigmented foveola

Hypopigmented foveola

Dark fovea

Dark fovea

Normal

Normal

Normal

Normal

Color Fundus Photography

Predominantly hyperreflective with
hyporeflective features

Mixed hyporeflective and
hyperreflective features

Hyporeflective fovea with central
hyperreflective area

Hyporeflective fovea with central
hyperreflective area

Hyporeflective fovea with central
hyperreflective area

Mixed hyporeflective and
hyperreflective features

Mixed hyporeflective and
hyperreflective features

Mixed hyporeflective and
hyperreflective features

Hyporeflective fovea

Hyporeflective fovea

Normal

Hyporeflective fovea

Hyporeflective fovea

Hyporeflective fovea

Hyporeflective fovea

Normal

Normal

Near-Infrared Reflectance

Author Manuscript
Table 1

Absent central macular AF

Absent foveal AF; increased AF
around larger lesion

Reduced foveal AF (greatly reduced
centrally) surrounded by increased
AF

Greatly reduced foveal AF
surrounded by increased AF

Greatly reduced foveal AF
surrounded by increased AF

Greatly reduced foveal AF
surrounded by increased AF

Greatly reduced foveal AF
surrounded by increased AF

Greatly reduced foveal AF

Reduced foveal AF

Reduced foveal AF

Increased AF resulting in foveal
stippling

Reduced foveal AF surrounded by
increased AF

Reduced foveal AF surrounded by
increased AF

Reduced foveal AF; increased AF in
inferior and temporal parafovea

Increased AF in temporal parafovea

Decreased macular pigment contrast

Increased AF in superior and nasal
fovea and parafovea

AF
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Stage 1, intact outer retina; stage 2, ISe line disruption; stage 3, optically empty space; stage 4, optically empty space with partial RPE disruption; and stage 5, complete RPE disruption and/or loss of the
ONL.

a

Abbreviations: AF, autofluorescence; BCVA, best-corrected visual acuity; ISe, inner segment ellipsoid; L, left; ONL, outer nuclear layer; R, right; RPE, retinal pigment epithelium; SD-OCT, spectraldomain optical coherence tomography.
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Table 2

Results of Genetic Analysis in Study Participants
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Case (Pair)

Gene

Allele 1 (Mutation)

Allele 2 (Mutation)

Author Manuscript

1 (1)

CNGB3

c.1432C>T (p.Arg478stop)

c.1432C>T (p.Arg478stop)

2

CNGA3

c.829C>T (p.Arg277Cys)

c.1228C>T (p.Arg410Trp)

3

No mutations found

None

None

4

CNGB3

c.1056-3C>G heterozygousa

None

5 (1)

CNGB3

c.1432C>T (p.Arg478stop)

c.1432C>T (p.Arg478stop)

6

CNGA3

c.1391T>G (p.Leu464Arg)b

c.1641C>A (p.Phe547Leu)

7

CNGA3

c.1391T>G (p.Leu464Arg)b

c.1621C>T (p.Leu541Phe)b

8

CNGA3

c.1070A>G (p.Tyr357Cys)b

c.830G>A (p.Arg277His)

9

CNGA3

c.829C>T (p.Arg277Cys)

c.847C>T (p.Arg283Trp)

10

CNGB3

c.1006G>T (p.Glu336stop)

c.1148delC (p.Thr383IIefsX13)

11 (2)

CNGB3

c.1208G>A (p.Arg403Gln) heterozygous

None

12 (2)

CNGB3 wild type

None

None

13 (3)

No mutations found

None

None

14 (3)

No mutations found

None

None

15

No mutations found

None

None

16 (4)

CNGA3

c.668G>A (p.Arg223Gln)b

c.667C>T (p.Arg223Trp)

17 (4)

CNGA3

c.668G>A (p.Arg223Gln)b

c.667C>T (p.Arg223Trp)

a

Novel sequence variant with unknown disease relevance.

b

Mutation was novel.
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